This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Porcu, P. Articles by Einhorn, L. H. Search for Related Content PubMed PubMed Citation Articles by Porcu, P. Articles by Einhorn, L. H. Social Bookmarking                            What's this?

Results of Treatment After Relapse From High-Dose Chemotherapy in Germ Cell Tumors

From the Division of Hematology/Oncology, Indiana University, Indianapolis, IN.

Address reprint requests to Lawrence H. Einhorn, MD, Indiana Cancer Pavilion, 535 Barnhill Dr, Rm 473, Indianapolis, IN 46202; email leinhorn{at}iupui.edu

PURPOSE: To identify therapy-related or patient-related characteristics that predict response and long-term survival after failure of high-dose chemotherapy (HDCT) for germ cell tumors (GCT).

PATIENTS AND METHODS: Between 1986 and 1997, 101 GCT patients relapsed after high-dose carboplatin and etoposide (VP-16) at Indiana University (Indianapolis, IN). Median time to relapse was 10 months (range, 1 to 17 months). HDCT was the first salvage treatment in 29 patients and second or later salvage treatment in 72 patients.

RESULTS: Fifty-four of 101 patients received post-HDCT treatment. Of these, 47 received chemotherapy, alone (n = 35) or in combination with surgery (n = 12). Seven patients underwent surgery alone. There were only 12 objective responses (three complete and nine partial responses) for 66 chemotherapy regimens given to 47 patients, for an overall response rate of 18.2%. Fifteen patients received platinum-based chemotherapy, with only one objective response. Chemotherapy was discontinued in 17% of cases because of toxicity. A longer interval between HDCT and post-HDCT treatment was the only variable that was associated with response. Five patients (4.9%) are disease-free at 30, 53, 57, 85, and 93 months after relapse. Of these, three responded to oral VP-16 and underwent resection of residual mediastinal, retroperitoneal, and inguinal cancer, respectively. One had resection of residual mediastinal yolk sac tumor, followed by oral VP-16. One relapsed with teratoma and received thoracoabdominal resection without chemotherapy.

CONCLUSION: Patients who experience disease progression after HDCT often receive further chemotherapy and/or surgery. Chemotherapy resulted in a response rate of less than 20%, with only three complete responses. All of the long-term survivors (4.9%) had surgery as a component of their post-HDCT regimen.

Presented in part at the Thirty-Fifth Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Bokemeyer, K. Oechsle, F. Honecker, F. Mayer, J. T. Hartmann, C. F. Waller, I. Bohlke, and C. Kollmannsberger Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group Ann. Onc., March 1, 2008; 19(3): 448 - 453. [Abstract] [Full Text] [PDF]

				L. H. Einhorn, M. J. Brames, B. Juliar, and S. D. Williams Phase II Study of Paclitaxel Plus Gemcitabine Salvage Chemotherapy for Germ Cell Tumors After Progression Following High-Dose Chemotherapy With Tandem Transplant J. Clin. Oncol., February 10, 2007; 25(5): 513 - 516. [Abstract] [Full Text] [PDF]

				G. Sonpavde, T. E. Hutson, and B. J. Roth Management of Recurrent Testicular Germ Cell Tumors Oncologist, January 1, 2007; 12(1): 51 - 61. [Abstract] [Full Text] [PDF]

				P. M. Bedano, M. J. Brames, S. D. Williams, B. E. Juliar, and L. H. Einhorn Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors J. Clin. Oncol., December 1, 2006; 24(34): 5403 - 5407. [Abstract] [Full Text] [PDF]

				O. Rick, C. Bokemeyer, S. Weinknecht, J. Schirren, T. Pottek, J.T. Hartmann, T. Braun, B. Rachud, L. Weissbach, M. Hartmann, et al. Residual Tumor Resection After High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Cancer J. Clin. Oncol., September 15, 2004; 22(18): 3713 - 3719. [Abstract] [Full Text] [PDF]

				C. Kollmannsberger, J. Beyer, R. Liersch, P. Schoeffski, B. Metzner, J.T. Hartmann, O. Rick, K. Stengele, K. Hohloch, C. Spott, et al. Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group J. Clin. Oncol., January 1, 2004; 22(1): 108 - 114. [Abstract] [Full Text] [PDF]

				D. A. Vaena, R. Abonour, and L. H. Einhorn Long-Term Survival After High-Dose Salvage Chemotherapy for Germ Cell Malignancies With Adverse Prognostic Variables J. Clin. Oncol., November 15, 2003; 21(22): 4100 - 4104. [Abstract] [Full Text] [PDF]

				A. Madani, K. Kemmer, C. Sweeney, C. Corless, T. Ulbright, M. Heinrich, and L. Einhorn Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors Ann. Onc., June 1, 2003; 14(6): 873 - 880. [Abstract] [Full Text] [PDF]

				K. Kawai, J. Miyazaki, S. Tsukamoto, S. Hinotsu, K. Hattori, T. Shimazui, and H. Akaza Paclitaxel, Ifosfamide and Cisplatin Regimen is Feasible for Japanese Patients with Advanced Germ Cell Cancer Jpn. J. Clin. Oncol., March 1, 2003; 33(3): 127 - 131. [Abstract] [Full Text] [PDF]

				C. Kollmannsberger, O. Rick, H.-G. Derigs, N. Schleucher, P. Schoffski, J. Beyer, R. Schoch, H.G. Sayer, A. Gerl, M. Kuczyk, et al. Activity of Oxaliplatin in Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group J. Clin. Oncol., April 15, 2002; 20(8): 2031 - 2037. [Abstract] [Full Text] [PDF]

				S. Hinton, P. Catalano, L. H. Einhorn, P. J. Loehrer Sr, T. Kuzel, D. Vaughn, and G. Wilding Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group J. Clin. Oncol., April 1, 2002; 20(7): 1859 - 1863. [Abstract] [Full Text] [PDF]